An innovative new solar-cell design which has the capability to drive down costs of solar cell manufacture, has been created by scientists at the University of Sheffield and energy technology company Power Roll.
* This article was originally published here
This Blog Is Powered By Life Technology™. Visit Life Technology™ At www.lifetechnology.com Subscribe To This Blog Via Feedburner / Atom 1.0 / RSS 2.0.
Saturday, 4 May 2019
Trump offshore drilling plan may be dead in the water, but there are better ways to lead on energy
President Trump's effort to expand offshore oil and gas exploration has stalled, and may be dead in the water. The newest obstacle is an April ruling in Alaska's U.S. District Court that blocked Trump's order to lift a ban on energy leasing in Arctic waters.
* This article was originally published here
* This article was originally published here
Monitoring the lifecycle of tiny catalyst nanoparticles
Nanoparticles can be used in many ways as catalysts. To be able to tailor them in such a way that they can catalyse certain reactions selectively and efficiently, researchers need to determine the properties of single particles as precisely as possible. So far, an ensemble of many nanoparticles is analysed. However, the problem of these investigations is that the contributions of different particles interfere, so that the properties of individual particles remain concealed. Researchers at Ruhr-Universiät Bochum in cooperation with colleagues from University of Duisburg-Essen and Technical University of Munich have developed a novel method in order to observe single nanoparticles before, during and after an electrochemical reaction. They depict the process in the journal Angewandte Chemie, published on 16 April 2019.
* This article was originally published here
* This article was originally published here
Study reveals reasons for different responses to anti-PD-1 checkpoint blockade immunotherapy
A team of researchers affiliated with Johns Hopkins University and Memorial Sloan Kettering Cancer Center has found some of the reasons for different responses to anti-PD-1 checkpoint blockade immunotherapy in cancer patients. In their paper published in the journal Science, the group describes their study of the therapy using mouse models, and what they found.
* This article was originally published here
* This article was originally published here
Subscribe to:
Posts (Atom)